Kempharm is looking at a possible resurgence in stock prices... The most recent news from the pharmaceutical company is positive, with a successful test of an ADHD prodrug. The current price looks like it is close to a fibbonaci level. If it breaks the downline and trends up, it would be a recovery from a strong downtrend, but the historical prices of this stock are within a fairly high range and it does not seem out of the norm for the price to go up again. The target price on finviz.com is $12 and there are some big insider trades that have taken place, both possible good indicators of the stocks expectancy to go up. From here a rise to $12 would be a 200% gain.
Trade active
Trade active:
Increasing position.